This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

An Open Label Study of Oral Enzastaurin in Patients With Cancer

This study has been completed.
Information provided by:
Eli Lilly and Company Identifier:
First received: March 29, 2006
Last updated: May 27, 2010
Last verified: May 2010

This study will collect further basic safety data on patients with cancer treated with enzastaurin. This study is not open to the public.

The purpose of the this study is to extend the clinical experience of patients who complete enzastaurin therapy per clinical pharmacology and biopharmaceutics studies conducted by Eli Lilly and Company and who may benefit from continued enzastaurin therapy.

Condition Intervention Phase
Neoplasms Cancer Drug: enzastaurin Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Study of Oral Enzastaurin HCl in Patients With Advanced or Metastatic Malignancies

Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • This study will collect basic safety data on patients cancer treated with enzastaurin. [ Time Frame: every cycle ]

Secondary Outcome Measures:
  • This study will document antitumor activity that may be observed with enzastaurin. [ Time Frame: baseline to measured progressive disease ]

Enrollment: 23
Study Start Date: March 2006
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: enzastaurin
500 mg, oral, daily, six 42 day cycles
Other Name: LY317615


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • You must have previously participated in and finished study JCAV, JCAY or other enzastaurin clinical pharmacology and biopharmaceutics studies. If you have had any other cancer treatment (chemotherapy, radiation, anti-cancer hormone therapy), you must have completed it at least 4 weeks ago before you can enroll in this study.
  • You must have a cancer for which no other therapy exists that can prolong your life. This may include patients with treated, stable brain cancer.
  • You must have lesions (areas of cancer in your body) that your doctor can either measure or detect.
  • You either must not be able to become pregnant, (because you've had surgery ["tubes tied" or hysterectomy], you've gone through menopause, or you've had previous radiation for cancer that made you sterile) or your potential to become pregnant must be reduced by the use of an approved birth control method (including intrauterine or barrier devices) during and for 3 to 6 months following the study.
  • You can be either male or female, and must be at least 18 years old.

Exclusion Criteria:

  • You must not have received treatment within the last 30 days with a drug other than enzastaurin that is still experimental (this means it has not received approval to be prescribed, except in a clinical trial).
  • You must not be pregnant or breastfeeding.
  • You must not have central nervous system (CNS) tumors (tumors in your brain and spinal cord). (However, patients who have stable CNS tumors and are taking steroid medication may be included.)
  • You must not have another serious disorder, including active infections that will interfere with your participation in the study.
  • You must not have a second cancer in addition to your primary cancer. Patients with adequately treated skin cancer or who have had another cancer in the past, but have been cancer free for more than 2 years, are eligible.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00309140

United States, Arizona
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Sun City, Arizona, United States, 85351
Sponsors and Collaborators
Eli Lilly and Company
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
  More Information

Additional Information:
Responsible Party: Chief Medical Officer, Eli Lilly Identifier: NCT00309140     History of Changes
Other Study ID Numbers: 10287
H6Q-MC-S001 ( Other Identifier: Eli Lilly and Company )
Study First Received: March 29, 2006
Last Updated: May 27, 2010 processed this record on July 26, 2017